Pheon Therapeutics Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
25
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$120M
- Investors
-
10
Pheon Therapeutics General Information
Description
Developer of advanced cancer treatment intended for targeting hard-to-treat cancers. The company leverages antibody drug conjugates to develop next-generation treatments, utilizing both novel and clinically validated monoclonal antibodies armed with proprietary payloads, enabling healthcare market to address unmet medical needs in solid tumors and liquid cancers through innovative and effective therapies.
Contact Information
Website
pheontx.comCorporate Office
- Lawes Open Innovation Hub
- Rothamsted Research, West Common, Hertfordshire
- Harpenden AL5 2JQ
- England, United Kingdom
Corporate Office
- Lawes Open Innovation Hub
- Rothamsted Research, West Common, Hertfordshire
- Harpenden AL5 2JQ
- England, United Kingdom
Pheon Therapeutics Timeline
Pheon Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series B) | 21-May-2024 | $120M | Completed | Clinical Trials - Phase 1 | ||
| 3. Later Stage VC (Series A2) | 04-Mar-2024 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC | 31-Jan-2018 | $2.07M | $5.6M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 19-Oct-2015 | $3.53M | $3.53M | Completed | Startup |
Pheon Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A 2 Preferred | ||||||||
| Series A 2 Preferred | 25,046,180 | $0.000125 | $2.38 | $2.38 | 1x | $2.38 | 44.36% | |
| Series A | 3,800,000 | $0.000125 | $1.25 | $1.25 | 1x | $1.25 | 6.73% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Pheon Therapeutics Comparisons
Industry
Financing
Details
Pheon Therapeutics Competitors (9)
One of Pheon Therapeutics’s 9 competitors is Araris, a Formerly VC-backed company based in Zurich, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Araris | Formerly VC-backed | Zurich, Switzerland | ||||
| Myricx Bio | Venture Capital-Backed | London, United Kingdom | ||||
| Sotio Biotech | Corporation | Prague, Czech Republic | ||||
| Adcendo | Venture Capital-Backed | Frederiksberg, Denmark | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom |
Pheon Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Pheon Therapeutics Patents
Pheon Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023306656-A1 | Antibody drug conjugates that bind cdcp1 and uses thereof | Pending | 15-Jul-2022 | ||
| AU-2023308528-A1 | Antibody-drug conjugates | Pending | 15-Jul-2022 | ||
| GB-202100200-D0 | Cytotoxic compounds | Inactive | 07-Jan-2021 | ||
| GB-202011653-D0 | Cytotoxic compounds | Inactive | 28-Jul-2020 | ||
| GB-2597532-A | Cytotoxic compounds | Inactive | 28-Jul-2020 | C07K5/06052 |
Pheon Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Pheon Therapeutics Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BVF Partners | Hedge Fund | Minority | ||
| Lightspeed Venture Partners | Venture Capital | Minority | ||
| Perceptive Advisors | Venture Capital | Minority | ||
| TCG Crossover Management | Venture Capital | Minority | ||
| Atlas Venture | Venture Capital | Minority |
Pheon Therapeutics FAQs
-
When was Pheon Therapeutics founded?
Pheon Therapeutics was founded in 2015.
-
Where is Pheon Therapeutics headquartered?
Pheon Therapeutics is headquartered in Harpenden, United Kingdom.
-
What is the size of Pheon Therapeutics?
Pheon Therapeutics has 25 total employees.
-
What industry is Pheon Therapeutics in?
Pheon Therapeutics’s primary industry is Drug Discovery.
-
Is Pheon Therapeutics a private or public company?
Pheon Therapeutics is a Private company.
-
What is the current valuation of Pheon Therapeutics?
The current valuation of Pheon Therapeutics is .
-
What is Pheon Therapeutics’s current revenue?
The current revenue for Pheon Therapeutics is .
-
How much funding has Pheon Therapeutics raised over time?
Pheon Therapeutics has raised $191M.
-
Who are Pheon Therapeutics’s investors?
BVF Partners, Lightspeed Venture Partners, Perceptive Advisors, TCG Crossover Management, and Atlas Venture are 5 of 10 investors who have invested in Pheon Therapeutics.
-
Who are Pheon Therapeutics’s competitors?
Araris, Myricx Bio, Sotio Biotech, Adcendo, and Adaptimmune Therapeutics are some of the 9 competitors of Pheon Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
